RT Journal Article
T1 Overexpression of Canonical Prefoldin Associates with the Risk of Mortality and Metastasis in Non-Small Cell Lung Cancer.
A1 Peñate, Xenia
A1 Praena-Fernández, Juan Manuel
A1 Romero Pareja, Pedro
A1 Enguix-Riego, María Del Valle
A1 Payán-Bravo, Laura
A1 Vieites, Begoña
A1 Gomez-Izquierdo, Lourdes
A1 Jaen Olasolo, Javier
A1 Rivin Del Campo, Eleonor
A1 Reyes, Jose Carlos
A1 Chávez, Sebastián
A1 Lopez Guerra, Jose Luis
K1 metastasis
K1 non-small cell lung cancer
K1 prefoldin
K1 survival
AB Canonical prefoldin is a protein cochaperone composed of six different subunits (PFDN1 to 6). PFDN1 overexpression promotes epithelial-mesenchymal transition (EMT) and increases the growth of xenograft lung cancer (LC) cell lines. We investigated whether this putative involvement of canonical PFDN in LC translates into the clinic. First, the mRNA expression of 518 non-small cell LC (NSCLC) cases from The Cancer Genome Atlas (TCGA) database was evaluated. Patients with PFDN1 overexpression had lower overall survival (OS; 45 vs. 86 months; p = 0.034). We then assessed the impact of PFDN expression on outcome in 58 NSCLC patients with available tumor tissue samples. PFDN1, 3, and 5 overexpression were found in 38% (n = 22), 53% (n = 31), and 41% (n = 24) of tumor samples. PFDN1, 3, and 5 overexpression were significantly associated with lower OS, lower disease-free survival (DFS), and lower distant metastasis-free survival (DMFS) for PFDN1 and 3 with a trend for PFDN5. In multivariate analysis, PFDN5 retained significance for OS (hazard ratio (HR) 2.56; p = 0.007) and PFDN1 for DFS (HR 2.53; p = 0.010) and marginally for DMFS (HR 2.32; p = 0.053). Our results indicate that protein response markers, such as PFDN1, 3, and 5, may complement mRNA signatures and be useful for determining the most appropriate therapy for NSCLC patients.
SN 2072-6694
YR 2020
FD 2020-04-24
LK https://hdl.handle.net/10668/28376
UL https://hdl.handle.net/10668/28376
LA en
DS RISalud
RD Apr 17, 2025